2025 American Academy of Neurology Abstract Website

Yusra Arafeh¹, Asmaa Zakria², Nada G. Hamam³, Amr K. Hassan⁴, Rnad Alajarmeh⁵, Mohamed Abed⁶, Bashar Zahir Alsalhen⁷
¹Faculty of Medicine, Jordan University of Science and Technology, ²Faculty of Medicine, Al-Azhar University, Gaza, Palestine., ³Faculty of Medicine, Kasr Al-ainy, Cairo University, Cairo, Egypt, ⁴Gavin Herbert Eye Institute, Faculty of Medicine, University of California, Irvine, ⁵General Pediatrics Department, Istiklal Hospital, Amman, Jordan, ⁶Faculty of Medicine, University of Tripoli, Tripoli, Libya, ⁷Faculty of Medicine Al-Balqa Applied University Medical student, Salt Jordan

Objective:

This study aims to analyze the rates of discontinuation and nonpublication in clinical trials related to gliomas, highlighting factors that contribute to these issues.

Background:

Gliomas are complex tumors that present significant challenges in research and treatment. Despite numerous clinical trials, a substantial number are discontinued or unpublished, impacting the overall knowledge base and treatment strategies for glioma patients.

Design/Methods:

We conducted a comprehensive analysis using data extracted from the ClinicalTrials.gov database. A total of 1,441 trials were identified and categorized based on their completion and publication status. We examined various trial characteristics, including participant demographics, enrollment size, study design, and funding sources. Statistical regression models were employed to identify predictors of trial discontinuation and nonpublication.

Results:

Among the identified trials, 1,092 (75.8%) were completed, while 349 (24.2%) were discontinued. Of the completed trials, 641 (44.5%) were published. Larger enrollment sizes and multi-center designs significantly reduced the likelihood of discontinuation (Odds Ratio [OR] = 0.215; p < 0.001) and nonpublication (OR = 0.481; p < 0.001).

Conclusions:

The high rates of discontinuation and nonpublication in glioma trials underscore the need for improved research methodologies. Focusing on larger, multi-center collaborations could enhance trial completion and publication rates, ultimately benefiting glioma research and patient outcomes.